


Influenza Session

Robert L. Atmar, MD
Chair, Influenza Work Group

Advisory Committee on Immunization Practices

June 24, 2020



Influenza Work Group

ACIP Members

Robert Atmar (Chair)

Kevin Ault

Hank Bernstein

Peter Szilagyi

Keipp Talbot

Ex Officio Members

Michael Cooper (NIH)

Cynthia Nolletti (FDA)

Chris Roberts (NIH)

Susan Wollersheim (FDA)

Consultants

Ed Belongia

Chip Walter

Jeff Duchin

Wendy Keitel

Jamie Loehr

Mark Mulligan

Kathy Neuzil

Liaison Representatives

Sarah Coles (AAFP)

Buddy Creech (PIDS)

Sarah Despres (Consumer Representative)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Denise Jamieson (ACOG)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Kelsey Young (NACI)

Matthew Zahn (NACCHO)

Recap of Influenza Session, February 2020

- Overview of early 2019-20 season influenza activity
- Early season 2019-20 influenza vaccine effectiveness estimates
- Presentation from Seqirus of pre-licensure study of quadrivalent adjuvanted inactivated influenza vaccine, Fludax Quadrivalent
 - Licensed by FDA in February 2020
- Presentation of safety data from a comparative RCT of high-dose and adjuvanted inactivated influenza vaccines among older adults

Recent Work Group Discussion

- Development of proposed 2020-21 ACIP Influenza Statement

Agenda Overview

- **2019-20 influenza activity, vaccine effectiveness, and safety updates**
- **Work Group considerations and proposed 2020-21 recommendations**